Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification… (NCT04806282) | Clinical Trial Compass
SuspendedNot Applicable
Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets
Stopped: Pause in study enrollment due to PI departure from NIH. IC leadership and the new PI have initiated a pause in the enrollment of new participants to assess the the study s operational capacity.
United States58 participantsStarted 2021-08-17
Plain-language summary
Background:
Disorders of hearing instability (HI) are poorly characterized and ineffectively treated. HI can cause fluctuations in hearing thresholds and speech understanding. Researchers want to use a specialized form of magnetic resonance imaging (MRI) and blood tests to learn more about HI.
Objective:
To characterize a cohort of people with HI and to correlate HI with other data, including hearing evaluations, as well as radiologic and immunologic biomarkers of inflammation over time.
Eligibility:
Adults ages 18-80 who have symptoms consistent with possible HI.
Design:
Participants will be screened with a medical and hearing history and medical record review.
Participants will have physical exams. Their head and neck will be examined. They will have blood drawn.
Participants will have hearing tests. They will wear headphones or foam earplugs. They will listen to different tones. They may describe what they hear.
Participants will have balance tests. They will wear goggles as they watch moving lights or while cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclining position, they will raise their head while clicking sounds are played into their ears.
Participants will have MRIs of the inner ear and brain. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRIs, participants will lie on a table that slides in and out of the scanner. Soft padding or a coil will be placed around their head. They will get a contrast agent through an intravenous catheter.
Participation will last up to 15 months.
...
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. No air-bone gaps in excess of 10 dB for 500-4000 Hz indicative of conductive HL in at least 1 ear.
✓. For females of reproductive potential: Negative pregnancy test at start of study
✓. Provision of signed and dated informed consent.
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. All genders, aged 18-80 years
✓. No air-bone gaps in excess of 10 dB for 500-4000Hz indicative of conductive HL in at least one ear.
✓. Normal middle ear function as indicated by normal 226 Hz tympanograms bilaterally, defined as middle ear pressure between plus minus 100 decaPascals, and peak compensated static compliance between 0.3-1.8 milliliters
✓. For females of reproductive potential: Negative pregnancy test at start of study
✕. Febrile illness within 2 weeks that could affect immune profiling\*
✕. Evidence of active outer or middle ear disease or anomaly (e.g. otitis media, stenotic ear canal, otorrhea)
✕. History of chronic, as defined by fluid in the middle ear for more than 4 months, or recurrent otitis media, as defined by more than 4 episodes of acute otitis media in one year.
✕. Current PE tubes
✕. Bilateral profound (Pure tone average (PTA) \> 90 dB HL) sensorineural hearing loss